Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

ConditionsLife Threatening Bleeding Factor Xa Inhibitor

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorAstraZeneca

About this trial

This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions.

Eligibility criteria

Qualifiers

All patients treated with this drug to neutralize the anticoagulant effect of a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) at onset of a life-threatening bleeding episode or a unarrestable bleeding episode.

Disqualifiers

N/A

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations65

Select a site below to view it on the map.

Sponsors and collaborators

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov